Adaptimmune Therapeutics plc (ADAP) Social Stream
ADAPTIMMUNE THERAPEUTICS PLC (ADAP) Price Targets From Analysts
Use the tables below to see what analysts covering ADAPTIMMUNE THERAPEUTICS PLC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-14 | 5 | $17 | $7 | $10.333 | $0.465 | 2122.15% |
| 2022-02-23 | 5 | $9 | $7 | $7.666 | $0.465 | 1548.6% |
| 2022-03-14 | 5 | $9 | $3 | $6.333 | $0.465 | 1261.94% |
| 2022-05-17 | 5 | $9 | $2 | $6 | $0.465 | 1190.32% |
| 2022-08-04 | 4 | $9 | $2 | $6 | $0.465 | 1190.32% |
| 2022-09-09 | 4 | $10 | $2 | $6 | $0.465 | 1190.32% |
| 2022-10-04 | 4 | $10 | $1.5 | $4.5 | $0.465 | 867.74% |
| 2022-11-09 | 5 | $10 | $1.5 | $5.875 | $0.465 | 1163.44% |
| 2022-11-14 | 6 | $10 | $3 | $6.25 | $0.465 | 1244.09% |
| 2023-01-05 | 7 | $10 | $3 | $6.666 | $0.465 | 1333.55% |
| 2023-03-06 | 6 | $10 | $3 | $6 | $0.465 | 1190.32% |
| 2023-05-12 | 6 | $10 | $2 | $5.8 | $0.465 | 1147.31% |
| 2023-08-10 | 7 | $10 | $1 | $5 | $0.465 | 975.27% |
| 2023-11-08 | 7 | $10 | $1 | $4.833 | $0.465 | 939.35% |
The Trend in the Analyst Price Target
Over the past 42 months, ADAP's average price target has gone down $8.
Over the past 44 weeks, ADAP's average upside potential has been 412.72%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-05 | 6 | 10 | 3 | 6.666 | 2.040 | 226.76% |
| 2023-03-06 | 6 | 10 | 2 | 5.800 | 1.320 | 339.39% |
| 2023-04-17 | 6 | 10 | 2 | 5.800 | 1.390 | 317.27% |
| 2023-08-10 | 7 | 10 | 1 | 5.000 | 0.815 | 513.5% |
| 2023-08-10 | 7 | 10 | 1 | 4.833 | 0.815 | 493.01% |
ADAP Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.14 | 4 | 0 | 2 | 1 | 1 | 7 |
The Trend in the Broker Recommendations
Over the past 13 months, ADAP's average broker recommendation rating worsened by 0.14.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ADAP as an investment opportunity.
- In terms of how ADAPTIMMUNE THERAPEUTICS PLC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1745.71% of that group.
- In terms of how ADAPTIMMUNE THERAPEUTICS PLC fares relative to all US stocks, note that its average analyst price target is greater than 101.35% of that group.
- ADAP has a lower variance in analysts' estimates than -1508.79% of all US stocks.
- To contextualize these metrics, consider that out of Healthcare stocks, ADAPTIMMUNE THERAPEUTICS PLC's number of analysts covering the stock is greater than 497.16% of them.
Stocks similar to ADAPTIMMUNE THERAPEUTICS PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are OTLK, TTNP, and BCDA.
View All Top Stocks by Price Target
Is ADAP a Buy, Hold or Sell? See the POWR Ratings now!